Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16826277 | 0.92 | DRD1 (0.43) | HTR1AHTR2AHTR7DRD2DRD1 | |
| SCHEMBL16825814 | 0.82 | TSHR (0.55) | HTR1AALDH1A1KDM4EHTR2AHTR7 | |
| SCHEMBL16825780 | 0.78 | LMNA (0.64) | HTR1AALDH1A1KDM4EHTR7KMT2A | |
| SCHEMBL18135548 | 0.78 | CHIT1 (0.52) | HTR1AALDH1A1KDM4EHTR7KMT2A | |
| SCHEMBL16825821 | 0.78 | CHIT1 (0.52) | HTR1AALDH1A1KDM4EHTR2AKMT2A | |
| SCHEMBL16825744 | 0.77 | CHIT1 (0.51) | HTR1AHTR2ADRD2 | |
| SCHEMBL16826406 | 0.77 | NOS3 (0.47) | HTR1AALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL16825820 | 0.75 | CHIT1 (0.52) | KDM4EDRD2GAA | |
| SCHEMBL16825903 | 0.74 | KDM4E (0.54) | HTR1AALDH1A1KDM4EHTR2AHTR7 | |
| SCHEMBL16825779 | 0.73 | KDM4E (0.47) | HTR1AALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | claimed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | claimed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3082805-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | The Institute For Drug Delivery (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INSTITUTE FOR DRUG DISCOVERY, LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095701-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | THE INSTITUTE FOR DRUG DELIVERY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297823-A1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | CMA1, CHIA, AADAC | HTR1A 1948/4885POLB 3344/4885ALDH1A1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.